Merck’s COVID-19 Pill to Be Produced by More Than Two Dozen Drugmakers

Medicines Patent Pool, a corporation supported by the U.N., introduced on Thursday that over two dozen generic drug makers will quickly start producing Merck’s COVID-19 capsule to make the therapy extra accessible in growing international locations.

The group stated that 27 generic drug makers would produce the capsule for 105 growing international locations. Particularly, agreements the businesses signed enable them to make each molnupiravir’s uncooked substances in addition to the ultimate product.

Molnupiravir is the COVID-19 therapy developed by Merck and Ridgeback Therapeutics. For sufferers with early indicators of COVID-19, the capsule is believed to chop the hospitalization charges in half.

The drugmakers producing the generic capsules come from 11 international locations together with Bangladesh, China, Egypt, Vietnam, Kenya and South Africa, the group stated.

“It is a important step towards guaranteeing world entry to an urgently wanted COVID-19 therapy,” Medicines Patent Pool’s government director Charles Gore stated in a press release.

Former FDA Commissioner Scott Gottlieb has beforehand referred to molnupiravir as a “game-changer.”

Earlier this week, Merck introduced that it had agreed to offer the United Nations Kids’s Fund (UNICEF) with as much as 3 million programs of its antiviral capsule.

“I’m happy with the truth that sufferers in these low- and middle-income international locations will achieve entry concurrently sufferers in international locations with increased incomes,” Merck’s CEO and President Robert Davis stated in a press release on the time.

This put up can be out there in:
Tiếng Việt